Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Gains from Sales and Divestitures (2017 - 2023)

Historic Gains from Sales and Divestitures for Ani Pharmaceuticals (ANIP) over the last 7 years, with Q1 2023 value amounting to $235000.0.

  • Ani Pharmaceuticals' Gains from Sales and Divestitures rose 4596.27% to $235000.0 in Q1 2023 from the same period last year, while for Mar 2023 it was $235000.0, marking a year-over-year increase of 4596.27%. This contributed to the annual value of $245000.0 for FY2022, which is 9600.0% up from last year.
  • Per Ani Pharmaceuticals' latest filing, its Gains from Sales and Divestitures stood at $235000.0 for Q1 2023, which was up 4596.27% from $245000.0 recorded in Q4 2022.
  • In the past 5 years, Ani Pharmaceuticals' Gains from Sales and Divestitures ranged from a high of $245000.0 in Q4 2022 and a low of $34000.0 during Q1 2021
  • Its 5-year average for Gains from Sales and Divestitures is $126937.5, with a median of $125500.0 in 2021.
  • In the last 5 years, Ani Pharmaceuticals' Gains from Sales and Divestitures plummeted by 3061.22% in 2021 and then surged by 37352.94% in 2022.
  • Over the past 5 years, Ani Pharmaceuticals' Gains from Sales and Divestitures (Quarter) stood at $42000.0 in 2019, then skyrocketed by 202.38% to $127000.0 in 2020, then dropped by 1.57% to $125000.0 in 2021, then surged by 96.0% to $245000.0 in 2022, then decreased by 4.08% to $235000.0 in 2023.
  • Its Gains from Sales and Divestitures stands at $235000.0 for Q1 2023, versus $245000.0 for Q4 2022 and $234000.0 for Q3 2022.